Skip to main content
. 2022 May 23;60(12):1041–1049. doi: 10.1038/s41393-022-00811-z

Table 2.

Objective 2, meta-regression analysis of the effect of BMC strategies on (A) locomotor recovery and (B) in vivo axonal regeneration; combinations tested in vitro and/or in vivo.

A Improvement in locomotor outcomes
Biomaterial-based combination Effect size (%) P > | t |  95% Conf. Interval Frequency % (n)
PLGA + combinations 41.5 0.064 [16.7, 66.3] 4.9 (5)
Chitosan + combinations 27.3 0.289 [10.2, 44.4] 13.7 (14)
HA + combinations 22.5 0.684 [1.1, 43.9] 6.9 (7)
Collagen + combinations 18.1 0.002 [6.9, 29.2] 22.6 (23)
Fibrin + combinations 14.8 0.703 [−2.1, 31.7] 13.6 (14)
Other biom. + combinations 30.7 0.064 [17, 44.4] 37.9 (39)
comparisons=102, p = 0.142, Tau2 = 520.7, I2 = 97.7%, adj R2 = 4.11%
B Improvement in axonal regeneration
Biomaterial-based combination Effect size (SD) P > | t |  95% Conf. Interval Frequency % (n)
Chitosan + combinations 2.9 0.235 [0.9, 4.8] 6 (7)
PLGA + combinations 2.8 0.289 [0.7, 4.8] 5.1 (6)
LOCS + combinations 2.4 0.391 [0.7, 4.0] 6.8 (8)
Alginate + combinations 1.9 0.838 [−0.4, 4.1] 4.27 (5)
Collagen + combinations 1.7 0.001 [0.8, 2.5] 24 (28)
Matrigel + combinations 1.4 0.836 [−0.6, 3.5] 4.3 (5)
Fibrin + combinations 0.3 0.067 [−1.2, 1.8] 8.5 (10)
Fibrin-PLGA + combinations −0.1 0.078 [−2, 1.8] 5.1 (6)
Other biom. + combinations 1.6 0.853 [0.5, 2.7] 35.9 (42)
comparisons = 117, p = 0.182, Tau2 = 2.2, I2 = 76.2%, adj R2 = 9.3%

PLGA poly(lactic-co-glycolic-acid), HA hyaluronic acid, LOCS linear ordered collagen scaffold.